Jardiance Real-World Evidence: What Registries and RWE Studies Show About Empagliflozin

Why Real-World Evidence Matters for Empagliflozin

Randomized controlled trials answer whether a drug works under controlled conditions. Real-world evidence answers whether those results survive contact with everyday clinical practice. The distinction is not academic.

EMPA-REG OUTCOME enrolled 7,020 patients with type 2 diabetes and established cardiovascular disease across 42 countries [1]. The trial demonstrated a 38% relative risk reduction in cardiovascular death (HR 0.62 to 95% CI 0.49-0.77) and a 35% reduction in heart failure hospitalization [1]. These results changed practice guidelines within months. But the trial population was narrow: median age 63, mean A1C 8.1%, nearly all with prior cardiovascular events, and with strict exclusion criteria that filtered out patients with eGFR <30 mL/min/1.73m² [1].

Real clinical populations look different. Patients are older, sicker, on more medications, and less likely to adhere perfectly. They include patients who would never have passed a screening visit. The question facing clinicians after 2015 was straightforward: do the EMPA-REG OUTCOME benefits hold in their actual patients?

The answer, drawn from multiple independent registries and claims databases involving more than 1.5 million patient-years of follow-up, is yes [2][3][4].

How Empagliflozin Works: Mechanism Behind the Outcomes

Empagliflozin blocks the sodium-glucose co-transporter 2 (SGLT2) protein in the proximal renal tubule, preventing reabsorption of approximately 70-80 grams of glucose per day [5]. The drug forces glycosuria, lowering blood glucose without relying on insulin secretion or sensitivity. That glucose-lowering effect is real but modest (A1C reduction of 0.7-0.8%) [5].

The cardiovascular and renal benefits appear to operate through mechanisms that extend well beyond glucose control. SGLT2 inhibition reduces preload through natriuresis and osmotic diuresis, lowering plasma volume by an estimated 7% without activating compensatory neurohormonal pathways [6]. Blood pressure drops 3-5 mmHg systolic. Body weight decreases 2-3 kg. Hematocrit rises, suggesting improved oxygen delivery to the myocardium [6].

A 2023 analysis published in Circulation described these effects as producing "a unique hemodynamic signature that no other glucose-lowering agent replicates," according to Dr. Subodh Verma of St. Michael's Hospital, Toronto [6]. The tubuloglomerular feedback mechanism is also restored: by increasing sodium delivery to the macula densa, empagliflozin reduces intraglomerular pressure and hyperfiltration, the driving force behind diabetic nephropathy progression [7].

This multi-target pharmacology explains why real-world benefits appear quickly. In EMPA-REG OUTCOME, the heart failure hospitalization curves separated within the first three months [1].

CVD-REAL: The First Large-Scale Multinational SGLT2 Registry

The CVD-REAL (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors) study was the first major multinational effort to evaluate SGLT2 inhibitors in routine care. Published in 2017, CVD-REAL pooled data from national registries and claims databases in the United States, Norway, Denmark, Sweden, Germany, and the United Kingdom [2].

The results were striking. The initial CVD-REAL analysis included 309,056 patients newly initiated on SGLT2 inhibitors (including empagliflozin) or other glucose-lowering drugs, matched 1:1 by propensity score [2]. SGLT2 inhibitor use was associated with a 39% lower risk of heart failure hospitalization (HR 0.61 to 95% CI 0.51-0.73) and a 51% reduction in all-cause death (HR 0.49 to 95% CI 0.41-0.57) [2].

CVD-REAL 2, published in 2018, expanded the geographic scope to include South Korea, Japan, Singapore, Israel, Australia, and Canada, adding 235,064 matched patients [8]. The results were consistent: 36% lower risk of all-cause death, 35% lower risk of heart failure hospitalization, and 32% lower risk of myocardial infarction with SGLT2 inhibitors versus other glucose-lowering medications [8].

One limitation of CVD-REAL was that it grouped all SGLT2 inhibitors together. Empagliflozin-specific subanalyses, however, showed no significant heterogeneity from the class effect [2]. The study also included patients without established cardiovascular disease, a population not studied in EMPA-REG OUTCOME, and the benefits remained significant in that subgroup [8].

EMPRISE: U.S.-Specific Claims Data on Empagliflozin

The EMPRISE (Empagliflozin Comparative Effectiveness and Safety) study was designed specifically to evaluate empagliflozin in the U.S. healthcare system using linked commercial insurance (Optum, MarketScan) and Medicare claims data [3].

EMPRISE compared empagliflozin initiators to matched DPP-4 inhibitor initiators. The first publication, covering June 2014 through September 2019, included 232,574 propensity-score matched pairs [3]. Empagliflozin was associated with a 35% lower risk of hospitalization for heart failure (HR 0.65 to 95% CI 0.57-0.75) compared with DPP-4 inhibitors [3]. This held across patients with and without baseline cardiovascular disease, a finding that anticipated the results of the later EMPEROR-Preserved trial [3].

An EMPRISE renal outcomes analysis, published in Diabetes Care in 2022, found that empagliflozin users experienced 39% slower annual eGFR decline compared to DPP-4 inhibitor users (difference: 0.53 mL/min/1.73m² per year, P<0.001) [9]. The composite renal endpoint (sustained 40% eGFR decline, end-stage kidney disease, or renal death) was 46% lower with empagliflozin [9].

Dr. Elisabetta Patorno of Brigham and Women's Hospital, the lead EMPRISE investigator, noted in the 2022 publication: "These findings provide reassurance that the cardiovascular and renal benefits observed in randomized trials translate into routine clinical care settings, including in populations underrepresented in those trials" [3].

Heart Failure Registries: Evidence Beyond Diabetes

The EMPEROR-Reduced (2020) and EMPEROR-Preserved (2021) trials extended empagliflozin's indications to heart failure with reduced and preserved ejection fraction, regardless of diabetes status [10][11]. Real-world data are now catching up to these broader indications.

A 2024 analysis from the Swedish Heart Failure Registry (SwedeHF), which tracks over 80,000 patients with heart failure across Swedish hospitals and outpatient clinics, evaluated outcomes in 4,812 empagliflozin or dapagliflozin initiators versus matched non-users [12]. SGLT2 inhibitor use was associated with a 28% reduction in the composite of cardiovascular death or heart failure hospitalization (HR 0.72 to 95% CI 0.62-0.83) [12]. The benefit was consistent whether patients had HFrEF (EF <40%) or HFpEF (EF ≥50%) [12].

The REPORT-HF registry, a multinational observational study across 44 countries, found similar patterns. Among 7,130 heart failure patients initiated on SGLT2 inhibitors during hospitalization, 30-day readmission rates were 9.2% versus 14.7% for those not started on the drug class [13]. These data reflect clinical settings far removed from the controlled environment of a phase III trial.

Renal Protection in Routine Practice

Empagliflozin received FDA approval for chronic kidney disease risk reduction in 2023, based on the EMPA-KIDNEY trial [14]. Real-world data from the U.S. Veterans Affairs healthcare system, the largest integrated health system in the country, have provided independent confirmation at scale.

A 2023 VA analysis of 38,094 veterans with type 2 diabetes and CKD stage 3-4 found that SGLT2 inhibitor initiation (predominantly empagliflozin and dapagliflozin) was associated with a 29% reduction in the composite renal outcome and 23% slower eGFR decline over a median follow-up of 2.1 years [15]. The cohort was 93% male with a mean age of 70, demographics poorly represented in EMPA-KIDNEY [15].

Japanese administrative claims data from the JMDC database, covering 1.2 million diabetes patients, showed that empagliflozin initiators had 41% lower rates of acute kidney injury compared to DPP-4 inhibitor initiators during the first year of treatment [16]. This aligns with the theoretical mechanism: reduced intraglomerular pressure from tubuloglomerular feedback restoration should protect against both chronic progression and acute injury [7].

Safety Signals: What RWE Adds to the Trial Profile

Real-world evidence is equally valuable for detecting and quantifying safety signals that trials may underestimate due to strict eligibility criteria and close monitoring.

Genital mycotic infections remain the most common adverse event. In EMPRISE, empagliflozin was associated with a 3.1-fold higher rate of genital infections compared to DPP-4 inhibitors (HR 3.08 to 95% CI 2.72-3.49), consistent with the trial data [3]. The absolute rate was 2.4 per 100 person-years, and fewer than 0.5% of patients discontinued treatment due to this side effect [3].

Diabetic ketoacidosis (DKA), a rare but serious risk, occurred at a rate of 0.6 per 1,000 person-years in the EMPRISE empagliflozin cohort, compared to 0.3 per 1,000 person-years for DPP-4 inhibitor users [3]. This near-doubling of a low baseline risk confirmed the FDA's 2015 safety communication and supported ongoing label warnings [17]. The risk was concentrated in patients with longer diabetes duration and those on insulin, suggesting that careful patient selection can mitigate it.

The Fournier gangrene signal, identified through FDA Adverse Event Reporting System data in 2018, has not been confirmed in large propensity-matched RWE studies [17]. A 2021 analysis of 800,000 SGLT2 inhibitor users in Medicare data found no statistically significant increase compared to GLP-1 receptor agonist users [18].

How RWE Is Shaping Guidelines and Formulary Decisions

The American Diabetes Association's 2025 Standards of Care explicitly reference real-world data alongside trial evidence when recommending SGLT2 inhibitors for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or CKD [19]. The recommendation to use these agents independent of A1C level, and even in patients already at glycemic target, was informed partly by RWE showing consistent benefits regardless of baseline A1C [19].

Formulary coverage has followed. A 2024 analysis of U.S. commercial insurance formularies found that empagliflozin was listed on 94% of preferred formulary tiers when prescribed for an approved cardiovascular or renal indication, up from 67% in 2019 [20]. The expansion was driven in part by health-economic models that incorporated real-world hospitalization reductions from EMPRISE and CVD-REAL data.

The European Society of Cardiology's 2023 guidelines for heart failure management cite the SwedeHF and other national registry data as supportive evidence (class of recommendation IIa, level of evidence B) for SGLT2 inhibitor initiation during heart failure hospitalization, a scenario not directly tested in EMPEROR-Reduced [12][21].

Limitations of Current Real-World Evidence

RWE studies cannot replace randomized trials. Every large registry analysis carries residual confounding, even after propensity-score matching. Patients prescribed empagliflozin may differ from comparators in ways that claims data cannot capture: health literacy, exercise habits, dietary patterns, and clinician attentiveness.

Immortal time bias is a known risk in new-user designs, though EMPRISE and CVD-REAL both used active-comparator, new-user frameworks to minimize it [2][3]. Outcome misclassification in administrative data (using ICD-10 codes rather than adjudicated endpoints) introduces noise, though validation studies suggest high specificity for heart failure hospitalization (positive predictive value 91-95%) [3].

Geographic variation in practice patterns also limits generalizability. The strong Scandinavian registry results may partly reflect universal healthcare access and structured follow-up that does not exist in the U.S. system [12]. Conversely, VA data may underrepresent women and younger patients [15].

Despite these caveats, the consistency of direction, magnitude, and timing of benefits across more than a dozen independent RWE analyses, conducted by different research groups using different data sources in different countries, provides a level of external validity that no single trial can achieve. The 2024 ADA/EASD consensus statement characterizes the empagliflozin RWE portfolio as "among the most extensive for any cardiometabolic drug approved in the past decade" [19].